search
Back to results

Cryotherapy in the Prevention of Chemotherapy-Induced Mucositis in Stem Cell Transplant

Primary Purpose

Mucositis, Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation

Status
Terminated
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Ice
Normal Saline Solution
Sponsored by
University of Florida
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Mucositis focused on measuring Etoposide, Cryotherapy

Eligibility Criteria

18 Years - 99 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Subjects age 18 year old or older who are eligible candidates for myeloablative autologous stem cell transplantation (ASCT).
  • Subjects receiving etoposide as part of their conditioning regimen with a planned total dose of ≥ 30 mg/kg.

Exclusion Criteria:

  • Subjects with prior radiation to head & neck region.
  • Subjects with known oropharynx involvement with their malignancy.
  • Subjects with a history of non-compliance or who lack capacity to give informed consent.

Sites / Locations

  • UF Health Shands Cancer Hopsital

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Cryotherapy Group (Group A)

Standard Oral Care Group (Group B)

Arm Description

Subjects in the intervention group will receive both standard oral care and cryotherapy. During the 30 minute cryotherapy periods, subjects will eat ice chips, and/or consume very cold or frozen foods. Cryotherapy will begin 15 minutes prior to the start time of each etoposide infusion. After 30 minutes of cryotherapy, subjects will begin the saline rinses. The subject should perform 3 saline rinses over 15 minutes. After 15 minutes of saline rinses, the 30-minute cryotherapy / 15-minute saline rinse cycles will be repeated until 30 min after completion of etoposide infusion (approximately 150 minutes). In addition, an oral care diary will be completed by the subject, and a daily oral assessment will be performed by the investigators.

Subjects in the control group will receive standard oral care only. At the beginning of each etoposide infusion, the subject will begin the saline rinses. The subject will perform 3 saline rinses over 15 minutes followed by 30 minutes of rest (no rinses). The 15-minute saline rinse / 30-minute rest cycles will be repeated until 30 minutes after the completion of the etoposide infusion (approximately 150 minutes). In addition, an oral care diary will be completed by the subject, and a daily oral assessment will be performed by the investigators.

Outcomes

Primary Outcome Measures

Number of participants that tolerate cryotherapy during each etoposide infusion
Time to onset, severity and duration of mucositis following etoposide administration

Secondary Outcome Measures

Full Information

First Posted
December 12, 2014
Last Updated
December 4, 2018
Sponsor
University of Florida
Collaborators
University of Florida Health
search

1. Study Identification

Unique Protocol Identification Number
NCT02326675
Brief Title
Cryotherapy in the Prevention of Chemotherapy-Induced Mucositis in Stem Cell Transplant
Official Title
Randomized Controlled, Open-Label Study on the Use of Cryotherapy in the Prevention of Chemotherapy-Induced Mucositis in Stem Cell Transplant Patients
Study Type
Interventional

2. Study Status

Record Verification Date
December 2018
Overall Recruitment Status
Terminated
Why Stopped
Interim analysis: results of the analysis showed no significant difference between the two study groups
Study Start Date
March 2015 (Actual)
Primary Completion Date
December 2017 (Actual)
Study Completion Date
December 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Florida
Collaborators
University of Florida Health

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Oral mucositis is a common complication of cancer therapy. Mucositis results from damage to the mucosal epithelium after delivery of chemotherapy or radiation treatments designed to treat the cancer. A number of treatment factors have been shown to influence the incidence and severity of mucositis, including chemotherapy type and dosage. High-dose chemotherapy before stem cell transplantation can cause severe oral mucositis and is often the side effect that patients find the most difficult to endure. Cryotherapy, keeping ice chips in the mouth during chemotherapy infusion, has been shown to prevent or alleviate mucositis caused by high-dose melphalan alone or given in combinations used in pre-transplant conditioning. One other drug notorious for causing severe mucositis is etoposide (VP-16). The specific aims of the study are: 1) to assess tolerability of cryotherapy given during chemotherapy administration; 2) to determine the efficacy of cryotherapy in reducing etoposide-induced mucositis.
Detailed Description
As a participant the following will happen: There will be a random assignment (much like the flip of a coin) to one of two study groups: Group A: Standard mouth care plus cryotherapy, or Group B: Standard mouth care. Standard Mouth Care plus Cryotherapy (Group A) Will receive the standard mouth care plus Cryotherapy and will consist of: Mouth care 3 times daily with a soft-bristle toothbrush or foam toothbrush Cryotherapy - beginning 15 minutes before etoposide chemotherapy starts, the consumption of ice chips and/or other very cold and frozen foods (popsicles, Italian Ice etc.) continuously for 30 minutes. o Short (1 to 3 minutes maximum) breaks over the course of the 30 minute period as long as at least 15 minutes are spent actively engaged in the cryotherapy Saline "swish and spit" mouth rinses - you will be asked to rinse your mouth with saline for approximately 30 seconds before spitting out the saline into the sink or basin o You will be asked to do this 3 times over 15 minutes following each 30 minute period of cryotherapy The cycle of 30 minutes of cryotherapy followed by 15 minutes of saline mouth rinses will be repeated until 30 minutes after the etoposide infusion (approximately 3 cycles for a typical 120 minute infusion). Standard Mouth Care (Group B) Randomization to the Standard Mouth Care group will consist of: Mouth care 3 times daily with a soft-bristle toothbrush or foam toothbrush Saline "swish and spit" mouth rinse - rinse the mouth with saline for approximately 30 seconds before spitting out the saline into the sink or basin At the beginning of each etoposide infusion, perform three 30-second saline rinses over 15 minutes followed by a 30-minute break from the rinses The cycle of 15-minute saline mouth rinses followed by 30-minute break periods will be repeated until 30 minutes after the etoposide infusion (approximately 3 cycles for a typical 120 minute infusion). The standard mouth care group, will not be permitted to eat ice chips or consume frozen foods during the times these times. All groups will have the following interventions and assessments performed: Mouth Care Diary - the time and type of mouth care and/or cryotherapy Mucositis Assessments - pain levels, appetite, ability to swallow liquids and/or food

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Mucositis, Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Stomatitis
Keywords
Etoposide, Cryotherapy

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
29 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Cryotherapy Group (Group A)
Arm Type
Active Comparator
Arm Description
Subjects in the intervention group will receive both standard oral care and cryotherapy. During the 30 minute cryotherapy periods, subjects will eat ice chips, and/or consume very cold or frozen foods. Cryotherapy will begin 15 minutes prior to the start time of each etoposide infusion. After 30 minutes of cryotherapy, subjects will begin the saline rinses. The subject should perform 3 saline rinses over 15 minutes. After 15 minutes of saline rinses, the 30-minute cryotherapy / 15-minute saline rinse cycles will be repeated until 30 min after completion of etoposide infusion (approximately 150 minutes). In addition, an oral care diary will be completed by the subject, and a daily oral assessment will be performed by the investigators.
Arm Title
Standard Oral Care Group (Group B)
Arm Type
Active Comparator
Arm Description
Subjects in the control group will receive standard oral care only. At the beginning of each etoposide infusion, the subject will begin the saline rinses. The subject will perform 3 saline rinses over 15 minutes followed by 30 minutes of rest (no rinses). The 15-minute saline rinse / 30-minute rest cycles will be repeated until 30 minutes after the completion of the etoposide infusion (approximately 150 minutes). In addition, an oral care diary will be completed by the subject, and a daily oral assessment will be performed by the investigators.
Intervention Type
Other
Intervention Name(s)
Ice
Other Intervention Name(s)
Cryotherapy,Ice Chips
Intervention Description
This group will receive cryotherapy, saline rinses, an oral care diary will be completed by the subject, and a daily oral assessment will be performed by the investigators as part of their participation.
Intervention Type
Other
Intervention Name(s)
Normal Saline Solution
Intervention Description
This group will receive saline rinses, an oral care diary will be completed by the subject, and a daily oral assessment will be performed by the investigators as part of their participation.
Primary Outcome Measure Information:
Title
Number of participants that tolerate cryotherapy during each etoposide infusion
Time Frame
Up to seven days prior to stem cell transplant.
Title
Time to onset, severity and duration of mucositis following etoposide administration
Time Frame
Participants will be followed starting on Day +1 post-transplant until they are discharged from the hospital, an expected average of 3-4 weeks.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
99 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Subjects age 18 year old or older who are eligible candidates for myeloablative autologous stem cell transplantation (ASCT). Subjects receiving etoposide as part of their conditioning regimen with a planned total dose of ≥ 30 mg/kg. Exclusion Criteria: Subjects with prior radiation to head & neck region. Subjects with known oropharynx involvement with their malignancy. Subjects with a history of non-compliance or who lack capacity to give informed consent.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jamie Dees, RN
Organizational Affiliation
UF Health
Official's Role
Principal Investigator
Facility Information:
Facility Name
UF Health Shands Cancer Hopsital
City
Gainesville
State/Province
Florida
ZIP/Postal Code
32608
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Cryotherapy in the Prevention of Chemotherapy-Induced Mucositis in Stem Cell Transplant

We'll reach out to this number within 24 hrs